Abstract:The number of successful drug development projects has been stagnant for decades despite major breakthroughs in chemistry, molecular biology, and genetics. Unreliable target identification and poor translatability of preclinical models have been identified as major causes of failure. To improve predictions of clinical efficacy and safety, interest has shifted to three-dimensional culture methods in which human cells can retain many physiologically and functionally relevant phenotypes for extended periods of time. Here, we review the state of the art of available organotypic culture techniques and critically review emerging models of human tissues with key importance for pharmacokinetics, pharmacodynamics, and toxicity. In addition, developments in bioprinting and microfluidic multiorgan cultures to emulate systemic drug disposition are summarized. We close by highlighting important trends regarding the fabrication of organotypic culture platforms and the choice of platform material to limit drug absorption and polymer leaching while supporting the phenotypic maintenance of cultured cells and allowing for scalable device fabrication. We conclude that organotypic and microphysiological human tissue models constitute promising systems to promote drug discovery and development by facilitating drug target identification and improving the preclinical evaluation of drug toxicity and pharmacokinetics. There is, however, a critical need for further validation, benchmarking, and consolidation efforts ideally conducted in intersectoral multicenter settings to accelerate acceptance of these novel models as reliable tools for translational pharmacology and toxicology. SIGNIFICANCE STATEMENT: Organotypic and microphysiological culture of human cells has emerged as a promising tool for preclinical drug discovery and development that might be able to narrow the translation gap. This review discusses recent technological and methodological advancements and the use of these systems for hit discovery and the evaluation of toxicity, clearance, and absorption of lead compounds.

A comprehensive overview of advanced dynamic in vitro intestinal and hepatic cell culture models

Development of novel tools for the in vitro investigation of drug-induced liver injury

An On-Chip Small Intestine–Liver Model for Pharmacokinetic Studies

Microfluidic models in liver drug metabolism research

Complex in Vitro Model: A Transformative Model in Drug Development and Precision Medicine

3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration

Cellular and Microbial In Vitro Modelling of Gastrointestinal Cancer

Organ-on-Chip Approaches for Intestinal 3D In Vitro Modeling

In vitro Models of the Small Intestine for Studying Intestinal Diseases

In Vitro Models for the Study of Liver Biology and Diseases: Advances and Limitations

In Vitro Human Liver Model for Toxicity Assessment with Clinical and Preclinical Instrumentation

Pharmacokinetic and pharmacodynamic insights from microfluidic intestine-on-a-chip models

Enhancing pre-clinical research with simplified intestinal cell line models

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

Dynamic in vitro intestinal barrier model coupled to chip-based liquid chromatography mass spectrometry for oral bioavailability studies

A microvascularized in vitro liver model for disease modeling and drug discovery

Dynamic, IPSC-derived hepatic tissue tri-culture system for the evaluation of liver physiology in vitro

Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development-Current State-of-the-Art and Future Perspectives